Cascadian Therapeutics (Cascadian Therapeutics) Debt-to-Equity : 0.00 (As of Dec. 2017)

View and export this data going back to 1991. Start your Free Trial

What is Cascadian Therapeutics Debt-to-Equity?

Cascadian Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2017 was $0.00 Mil. Cascadian Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2017 was $0.00 Mil. Cascadian Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2017 was $109.04 Mil. Cascadian Therapeutics's debt to equity for the quarter that ended in Dec. 2017 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cascadian Therapeutics's Debt-to-Equity or its related term are showing as below:

CASC's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

Cascadian Therapeutics Debt-to-Equity Historical Data

The historical data trend for Cascadian Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cascadian Therapeutics Debt-to-Equity Chart

Cascadian Therapeutics Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Debt-to-Equity

Get a 7-Day Free Trial

Cascadian Therapeutics Quarterly Data
	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cascadian Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Cascadian Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cascadian Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cascadian Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cascadian Therapeutics's Debt-to-Equity falls into.

Cascadian Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cascadian Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	109.036
	=	0.00

Cascadian Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	109.036
	=	0.00

Cascadian Therapeutics (NAS:CASC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cascadian Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cascadian Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cascadian Therapeutics (Cascadian Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cascadian Therapeutics Inc (NAS:CASC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cascadianrx.com

Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.

Executives

Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Gwen A. Fyfe	director	C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Steven P James	director	C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Julia Marie Eastland	officer: CFO & CBO	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Christopher S Henney	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Robert Azelby	director	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Scott Dunseth Myers	director, officer: President and CEO	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Growth Equity Opportunities Iv, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 15 Gp, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Jon Sakoda	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025

Cascadian Therapeutics (Cascadian Therapeutics) Headlines

From GuruFocus

Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines

By Holly LaFon Holly LaFon • 07-12-2016

Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics

By Kyle Ferguson Kyle Ferguson • 07-11-2016

Value Betting with Special Situations: Lessons from the World of Gambling

By Henniker82 Henniker82 • 03-05-2013